Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Adaptor-related protein complex 5 subunit mu-1 (AP5M1) is the medium subunit of the AP-5 adaptor protein complex, a putative fifth member of the AP complexes involved in vesicular trafficking, especially endosomal transport. AP5M1 (also known as MUDENG or MuD) is expressed throughout the body, localizing to the cytosol, late endosome, lysosome, mitochondria, and endoplasmic reticulum. It regulates the expression of the pro-apoptotic protein BAX and can induce cell death in tumor cells, particularly via mechanisms linked to Fas-mediated and TRAIL-mediated apoptosis. AP5M1 features a conserved adaptin domain with caspase-3 binding sites, which allows it to modulate apoptosis, possibly providing an anti-apoptotic effect in the context of TRAIL signaling by sequestering caspase-3 away from crucial substrates such as BID. There is no current evidence that AP5M1 is a direct therapeutic target for any drugs.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Adaptor-related protein complex 5 subunit mu-1 (AP5M1).